Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $25M

Overview

Javara is a private, US-based clinical research services company founded in 2018, pioneering a 'Clinical Research as a Care Option' (CRAACO) model. By embedding research infrastructure within established healthcare provider networks like Atrium Health and Privia Health, it seeks to solve chronic industry inefficiencies in patient recruitment and retention. This integrated approach targets faster, more diverse trial enrollment to reduce drug development timelines for its biopharma and CRO clients.

Digital HealthClinical Research

Technology Platform

An integrated, tech-enabled service platform that embeds clinical trial infrastructure into community healthcare systems. It utilizes centralized resources, standardized operations, and tools like an A.I. Screening Assistant to connect patients with trials through their existing providers.

Funding History

1
Total raised:$25M
Series A$25M

Opportunities

The growing demand for decentralized trial elements and diverse patient populations presents a major opportunity.
Regulatory pressure for inclusive research and the biopharma industry's need to reduce development timelines and costs align perfectly with Javara's integrated community-based model.

Risk Factors

Key risks include execution complexity in managing a distributed network of healthcare partners, potential reluctance from traditional sponsors to adopt a non-standard site model, and dependency on the continued cooperation and stability of its strategic health system partners.

Competitive Landscape

Javara competes with traditional CROs (like IQVIA, PPD) and large site networks, but its integrated IRO model is differentiated. Direct competitors include other decentralized clinical trial (DCT) platform providers and niche CROs focusing on community integration, but Javara's deep, operational embedding within health systems creates a significant barrier to entry.